思替卡韦治疗乙肝肝硬化患者的甲状腺激素变化

Thyroid Hormone Changes of Entecavir in Treatment of Patients with Hepatitis B Liver Cirrhosis

目的探讨分析思替卡韦治疗乙肝肝硬化患者的甲状腺激素变化。方法通过方便选取2016年4月—2017年8月期间该院收治的乙肝肝硬化患者80例作为该次研究组,同期选择40名健康体检者作为对照组。对研究组患者行恩替卡韦治疗,连续治疗周期为24周。对比分析治疗前后研究组患者的甲状腺激素T3、T4、FT3、FT4、TSH具体指标变化。结果通过对患者行恩替卡韦治疗,研究组患者治疗前后甲状腺激素存在明显变化,治疗前相较对照组T3、T4、FT3、FT4水平指标明显下降,TSH指标由原本的(5.28±2.08),逐步转变为(2.62±1.14),差异有统计学意义(t=8.914,P<0.05)。治疗24周之后,HBV-DNA转阴组患者甲状腺激素T3、T4、FT3、FT4、TSH、AST、PT、ALB,相较HBV-DNA未转阴组患者改善较明显(P<0.05)。结论通过对乙肝肝硬化患者行恩替卡韦药物治疗,可以取得显著治疗疗效,明显改善患者的肝功能以及甲状腺激素水平,同时甲状腺激素水平,还能够作为肝病患者的病情严重与否的判断治疗,提供充分临床确诊及预后治疗依据。

Objective To study and analyze the thyroid hormone changes of entecavir in treatment of patients with hepatitis B liver cirrhosis. Methods 80 cases of patients with hepatitis B liver cirrhosis admitted and treated in our hospital from April 2016 to August 2017 were convenient selected as the research group, and 40 cases of healthy physical examination people were selected as the control group, and the research group were treated with entecavir, for 24 weeks in a row, and the specific indexes changes of thyroid hormone T3, T4, FT3, FT4, TSH in the research group were analyzed and compared before and after treatment. Results The thyroid hormones obviously changed in the research group before treatment, and the T3, T4, FT3, FT4 levels obviously decreased compared with those in the control group before treatment, and the TSH index changed from（5.28±2.08） to（2.62±1.14）, and the difference was obvious（t=8.914,P0.05）, in 24 weeks after treatment, the T3, T4, FT3, FT4, TSH, AST, PT, ALB were improved more of HBV-DNA negative group compared with those in the nonnegative group（P0.05）. Conclusion The treatment effect of entecavir in treatment of patients with Hepatitis B liver cirrhosis is obvious, which can obviously improve the liver function and thyroid hormone level, and the thyroid hormone level can be used as the determination indicator of severity of liver disease, thus providing basis for the clinical confirmation and prognosis.